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In Australia and New Zealand, by contrast with much of the developed world, insurance
companies can use genetic test results to refuse cover or increase premiums for
mutually-rated insurance products, including life, income protection and disability
insurance. Genetics professionals regularly discuss insurance implications with clients
and report the issue as a clinical challenge, yet no studies have examined clinical
practices or opinions. This study surveyed genetic counsellors and clinical geneticists
from Australia and New Zealand to (i) investigate variability in professional practice
across the Australasian clinical genetic workforce relating to the insurance implications
of genetic testing, and (ii) ascertain views regarding current regulation of the issue.
There was considerable variability in training and clinical policies, especially around
the communication of insurance implications. Almost half of participants reported
receiving no training on the insurance implications of genetic testing, and almost 40%
were unsure whether they could adequately advise clients. A number of deficits in
professional knowledge and understanding of the issue were identified. Widespread
concerns regarding regulation of this area were reported, with <10% of Australian
participants considering current Australian regulations as adequate to protect clients
from genetic discrimination. The findings from this study highlight scope for greater
education, consistency and professional training on the issue of genetics and insurance
in Australasia, and strong agreement about the need for regulatory reform.
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INTRODUCTION
In Australia and New Zealand, insurance companies can use genetic test results to refuse cover,
increase premiums or exclude aspects of cover for mutually-rated life insurance products, including
life, income protection and total disability insurance. Genetic test results cannot be used for health
insurance in Australia, which is community rated (1), but can be used in New Zealand for this
purpose.
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Many countries, including Canada, the UK and much of
Europe, have banned or restricted the use of genetic information
by life insurance companies (2, 3). In Australasia1 however,
life insurance companies can require applicants to disclose any
results of genetic testing known to the applicant. This includes
genetic results from clinical testing as well as research and
online, direct-to-consumer genetic tests (4). Insurers can then use
that information, with other health and lifestyle information, in
making underwriting decisions.
The use of genetic test results by life insurers is particularly
relevant for individuals who are unaffected by disease and
undergoing clinical predictive genetic testing (e.g., for
neurogenetic conditions, such as Huntington disease or
cancer predisposition, such as Lynch syndrome). Emerging
research demonstrates that some at-risk individuals are deterred
from having predictive genetic testing (5, 6) and choosing not to
participate in genomic research (7) because of insurance fears.
Life insurers in Australia and New Zealand are currently self-
regulated [managed by the peak industry body in each country,
both named the Financial Services Council (FSC)], without
government oversight (8). It can be argued that this creates
uncertainty for consumers and genetics professionals regarding
how insurers will use genetic information and raises numerous
other concerns which have been discussed elsewhere (8). It is
argued that the Australian FSC’s recent policy changes are only
likely to increase this uncertainty, as the new policy recommends
insurers ask whether applicants are “considering” a genetic test.
Given the applicant at this stage has no knowledge of genetic test
information that the insurer does not have, there would appear to
be no imbalance of information if consideration of a genetic test
is not revealed to the insurer (8).
Clinical genetics professionals are in a unique position to
inform clients about insurance implications of genetic testing
before testing takes place (9). Guidance from the Human
Genetics Society of Australasia (HGSA), the representative body
for human genetics professionals in Australia and New Zealand,
indicates genetics professionals should include a discussion
of relevant insurance issues during consultations (10, 11).
Two published Australian studies have shown that genetics
professionals routinely discuss life insurance implications with
clients during pre-test counselling sessions (12, 13). This takes
time in sessions that cover a significant amount of information;
however, to our knowledge there are no Australasian studies
exploring professional practice in this area.
This study was designed to determine if variability exists in
workplace trends, training policies and opinions related to the
issue of genetic testing and insurance, and its current regulation.
METHODS
Participants
Genetics professionals were recruited through the HGSA by
email to members of the Australasian Society of Genetic
Counsellors and the Australasian Association of Clinical
Geneticists, the HGSA newsletter, and the 2017 HGSA Annual
1Used here to refer to Australia and New Zealand.
Scientific Meeting. Although the focus of the project was on
Australian practice, the HGSA includes Australian and New
Zealand practitioners and any interested participants were
encouraged to participate. A screening question was used to
include only genetics professionals who see clients considering
genetic testing.
Data Collection and Analysis
The study utilised an online survey (Appendix 1 in
Supplementary Material), which was developed and refined
through consultation with statistical and subject matter experts,
including genetic counsellors, geneticists, and law and ethics
experts. The survey aimed to measure (1) presence and adequacy
of training and policies held by genetics services regarding
communication of insurance issues with clients; (2) knowledge
and practice of genetics professionals; and (3) attitudes regarding
regulation of the area. The published literature was reviewed and
relevant validated scales were considered, however, no scales
were suitable for the topics in the survey.
The survey was open for data collection from 7 June 2017 until
18 August 2017. Data were collected andmanaged using REDCap
(Research Electronic Data Capture) electronic data capture tools
hosted at Murdoch Children’s Research Institute (14). Online
survey data were de-identified and exported for analysis using
STATA 14 (StataCorp, Texas). No calculations related to power
or statistical significance were performed for this exploratory
study. Qualitative data were collected from selected participants
through telephone interviews, but these data are not reported in
this paper.
Ethics Committee Approval
This study was completed in partial fulfilment of the
requirements for the Master of Genetic Counselling, University
of Melbourne, Victoria, Australia, and was supported by the
Victorian Government’s Operational Infrastructure Support
Program. Approval for the project was granted by the Human
Ethics Advisory Committee, Department of Paediatrics,
University of Melbourne on 12 May 2017.
RESULTS
Participant Response
Eighty-seven genetics professionals participated in the online
survey. The number of participants who completed each
question (n value) is reported. The demographics of the survey
participants are set out in Table 1.
Figure 1 summarises results about training, policy,
knowledge, professional practice and views on regulation
presented below.
Training, Policy, Knowledge
Forty-nine percent (n = 43/87) of participants reported the
genetics service where they work had not provided training about
the insurance implications of genetic testing (Figure 1, box 1),
and 20% of participants who had received training (n = 9/44)
felt this training was inadequate. Sixty-one percent (n = 53/87)
of participants stated that either their genetics service did not
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TABLE 1 | Participant demographics.
Demographic Category Number of online survey
participants (n = 87)
Gender Male 8 (9%)
Female 79 (91%)
Profession Medically trained genetics
professionals
15 (17%)
Genetic counsellors 72 (83%)
Years of
experience
0–5 years 34 (39%)
6–10 years 17 (20%)
11–15 years 14 (16%)
15–20 years 15 (17%)
>20 years 7 (8%)
Appointments per
fortnight
0–5 13 (15%)
6–10 37 (42%)
11–20 31 (36%)
>20 6 (7%)
Location Australian Capital Territory 1 (1%)
New South Wales 23 (27%)
New Zealand 6 (7%)
Queensland 7 (8%)
Tasmania 2 (2%)
South Australia 6 (7%)
Victoria 27 (31%)
Western Australia 15 (17%)
have a policy (44%, n = 38/87) or they were unsure whether
there was a policy (17%, n = 15/87) regarding communicating
with clients about the insurance implications of genetic testing
(Figure 1, box 2).
Forty-six percent of participants (n = 36/79) indicated their
genetics service has one standard consent form for all types
of genetic testing, and 53% (n = 19/36) of these do not
include a statement about insurance implications (Figure 1,
box 3).
Thirty-nine percent (n = 34/87) of participants did not
have (25%, n = 22/87) or were unsure of having (14%, n =
12/87) sufficient knowledge about the insurance implications
of genetic testing to properly advise clients (Figure 1, box
4). Of these, 71% (n = 24/34) had <10 years’ professional
experience. Of participants with more than 10 years’ experience,
27% (n = 10/36) did not have or were unsure of having
sufficient knowledge. Fifteen percent of Australian participants
(n = 11/74) believe that genetic information could be used
for health insurance policies in Australia,2 which is incorrect
(1). Ninety-three percent (n = 74/79) of participants stated it
could be used for life insurance, 68% (n = 54/79) for disability
insurance, 91% (n= 72/79) for income protection insurance and
42% (n = 33/79) for travel insurance, indicating variability in
knowledge of current regulation. Travel insurance is a mutually
2Health insurance is specifically protected from risk rating in Australia. This
specific protection does not apply in New Zealand and so data from New Zealand
participants was excluded from this question.
rated insurance product,3 meaning providers can use genetic test
results to assess risk, though their decisions, in theory, must
have a reasonable basis. Three participants of 79 (4%) did not
knowwhich insurance policies genetic information could be used
for.
Eighty-five percent (n = 68/80) of participants had read the
Centre for Genetics Education (CGE)’s Fact Sheet 20 titled, “Life
insurance products and genetic testing in Australia” (15). This
document, to the authors’ knowledge, is the most comprehensive
resource currently available to professionals and the public on
this issue. Eleven of the 12 participants who had not read
the Fact Sheet were not made aware of its existence by their
workplace.
Professional Practice
All participants stated that communicating information about
insurance implications of predictive genetic testing in adults is
very important (n= 60/79) or somewhat important (n= 19/79),
and 99% (n = 78/79) consider that this communication is their
responsibility (Figure 1, box 5).
Ninety-four percent (n= 74/79) of participants always discuss
insurance implications with unaffected adults considering
predictive genetic testing. Practice differed for other kinds of
testing (diagnostic testing in children/adults, predictive testing
in children, and prenatal testing). Participants were next most
likely to discuss insurance implications in predictive testing
in unaffected children (75% always discussed, n = 59/79)
and least likely in prenatal testing (3% always discussed, n =
2/79).
Use of Genetic Results by Insurers and
Regulation
Twenty-two percent (n = 16/73) of participants have had direct
experience with a client/s who had an adverse policy outcome
on the basis of genetic test results (Figure 1, box 6). Ninety-five
percent of participants (n= 70/74) sometimes (n= 19/74), often
(n= 24/74) or always (n= 27/74) discuss with clients the option
to go away and organise their insurance before having genetic
testing (Figure 1, box 7). Only three percent of participants (n =
2/74) agreed with the suggestion that this practice may amount
to fraud (Figure 1, box 8).
Fifty-nine percent (n = 43/73) of survey participants
considered insurers should not be allowed to ask whether
applicants are considering having a genetic test, while 21% (n =
15/43) thought it should be allowed. Twenty percent (n= 15/73)
were unsure (Figure 1, box 9).
Of the Australian participants surveyed, 9% (n = 6/69)
considered current Australian regulations adequate to protect
clients from genetic discrimination. Fifty-two percent (n =
36/69) felt they were inadequate and 39% (n = 27/69) were
unsure (Figure 1, box 10). When asked about types of regulation
that could be implemented, 62% (n= 43/69) considered Australia
should have separate legislation regulating the use of genetic
information by insurers. Two percent (n = 1/69) of participants
answered no to this question, and 36% (n = 25/69) were
3It should be noted that FSC policies do not relate to travel insurance.
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1. Has your gene!cs service provided any [formal or informal] training 
regarding insurance implica!ons of gene!c tes!ng? (n=87)  
 
 
 
No, 49% (43)
Yes, 51% (44)
2. Does your gene!cs service have an agreed policy regarding 
communica!ng with clients about insurance implica!ons of gene!c 
tes!ng? (n=87) 
 
I don't know, 17% (15)
No, 44% (38)
Yes, 39% (34)
4. Do you feel you have suﬃcient knowledge about the insurance 
implica!ons of gene!c tes!ng to properly advise clients? (n=87)  
unsure, 14% (12)
no , 25% (22)
yes, 61% (53)
6. Have you had direct experience with a client/s who has had an 
adverse policy outcome on the basis of gene!c test results? (n=73) 
 
 
 
No, 78% (57)
Yes, 22% (16)
7. How o#en do you discuss with clients the op!on to go away and 
organise their insurance before having gene!c tes!ng? (n=74) 
Never, 5% (4)
Some!mes, 26% (19)
O#en, 32% (24)
Always, 37% (27)
8. There has been some sugges!on by insurance companies that this 
may amount to fraud. Do you agree? (n=74) 
 
 
I don't know, 17% (13)
No, 80% (59)
Yes, 3% (2)
10. Do you think the current regula!ons in Australia regarding 
insurance and gene!cs are adequate to protect clients from gene!c 
discrimina!on? (n=69 Australian par!cipants) 
 
I don't know, 39% (27)
No, 52% (36)
Yes, 9% (6)
11. Do you think Australia should have separate legisla!on regula!ng 
the use of gene!c informa!on by life, disability, income protec!on and 
travel insurance companies? (n=69 Australian par!cipants) 
 
 
I don't know, 36% (25)
No, 2% (1)
Yes, 62% (43)
9. The current version of the Financial Services Council Gene!c Tes!ng 
Policy recommends that life insurers ask applicants: "Have you ever 
had or are you considering having a gene!c test where you have 
received (or are currently awai!ng) an individual result?"  
Do you think that this should be allowed? (n=73) 
 
I don't know, 21% (15)
No, 59% (43)
Yes, 20% (15)
12. Do you think Australia should have a moratorium (ban) on the use 
of gene!c informa!on by life, disability, income protec!on and travel 
insurance companies? (n=69 Australian par!cipants) 
 
 
I don't know, 38% (26)
No, 23% (16)
Yes, 39% (27)
3. [For services with one standard consent form], does it contain a 
statement about insurance implica!ons? (n=36) 
 
 
 
no, 53% (19)
yes, 47% (17)
5. Whose responsibility is communica!ng the implica!ons of gene!c 
tes!ng with clients? [select all that apply] (n=79) 
 
I don't know, 17% (14)
Nobody's responsibility, 0%
Someone outside my workplace, 8% (6)
Someone else at my workplace, 5% (4)
My responsibility, 99% (78)
FIGURE 1 | Results about training, policy, knowledge, professional practice, and views on regulation.
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TABLE 2 | Recommendations.
No Issue Recommendation
1 Some genetics professionals are inadequately equipped to advise client Genetics services work with the HGSANHMRC, and the Centre for Genetics
Education to develop training modules, resources and national guidelines
regarding insurance issues, and maintain a regularly-updated resource page for
access by genetics professionals.
2 Variability of professional practice
3 Lack of consistency in consent forms Genetics services work with the HGSA, state and territory Health Departments
(with reference to the work already undertaken in NSW), the NHMRC and other
interested bodies, such as the Australian Genomics Health Alliance (AGHA), to
build on existing national precedents and develop national consent forms
regarding genetic testing that include information about the insurance
implications of genetic testing.
4 Regulation inadequate to protect clients from genetic discrimination The Australian federal government must consider reforms regulating the use of
genetic test results by insurers.
unsure (Figure 1, box 11). Thirty-nine percent (n = 27/69)
of participants considered Australia should ban the use of
genetic information by insurers, while 23% (n = 16/69) did not
agree with a ban and 38% (n = 26/69) were unsure (Figure 1,
box 12).
DISCUSSION
Results of this study suggest many Australasian genetics
professionals, while acknowledging it as a major issue in
clinical practice, do not feel adequately equipped to advise
clients regarding the insurance implications of genetic
testing.
Practice Implications
Genetic professionals have a fundamental obligation to promote
informed consent and ensure clients understand the implications
of genetic testing (16). Where genetics professionals have
either self-declared, or demonstrated through incorrect survey
responses, a lack of knowledge, the implications are significant
for their practice. Although the majority of professionals self-
reporting inadequate knowledge in this area had <10 years’
experience, almost 30% had >10 years’ experience, and more
than a quarter of the participants with >10 years’ experience
reported inadequate knowledge. Although, as acknowledged in
the Limitations section, these numbers are reasonably small,
which limits the generalisability of this study, the results indicate
that this lack of knowledge may be persistent even in more
experienced professionals. Further, as the genetics workforce
is growing, with a large number of junior professionals, this
data represents a proportion of the workforce whose training
and knowledge needs must be addressed. The current HGSA
guidelines on genetic counselling practice place responsibility
on genetics professionals to discuss insurance issues with
clients (11), but do not allocate responsibility for appropriate
training and resourcing of professionals in this area. While the
results suggest that that CGE’s Fact Sheet 20 has been widely
disseminated and most professionals are familiar with it, gaps in
knowledge persist.
Almost all participants always discuss insurance implications
of predictive testing with unaffected adult clients, despite
evidence of professional knowledge limitations and a number
self-reporting insufficient knowledge to adequately advise clients.
This suggests that genetics professionals may not always provide
correct information to clients on this issue. A Canadian
study (9) has shown that genetic counsellors are comfortable
discussing matters about which they are uncertain because
discussions of uncertainty are routine in genetic counselling. In
these circumstances, there is a risk that the legal implications
could be poorly understood and incorrectly communicated to
clients (9).
One mechanism to ensure consistent practice in Australasia
is to include insurance implications on clinical consent
forms signed by a client before genetic testing takes place,
although this will not necessarily ensure informed consent.
The findings showed variation across genetics services in this
regard, indicating further inconsistency in client experience and
mirroring international findings (17). The New South Wales
Ministry of Health has recently implemented a new suite of
consent forms for genetic and/or genomic testing in that state
(18). It may be timely for genetics services to review their consent
forms and ensure that the information on insurance issues are
correct and consistent across sites. This will also assist with
ensuring fully informed consent is obtained prior to testing, but
would not negate the need for an explanation or discussion for
many patients.
In addition, genetics services and state Health Departments, as
well as interested bodies, such as the National Health andMedical
Research Council (NHMRC) and the Australian Genomics
Health Alliance (AGHA) could collaborate to build on existing
precedents and develop nationally consistent training modules
and resources, and model consent clauses that could be adapted
to each clinic’s needs. However, while a collaborative approach
to the insurance implications of genetic testing will assist
with national consistency, each genetics service must ultimately
take final responsibility for maintaining appropriate policies,
communicating them to staff and ensuring knowledge and
practice are up-to-date. Given the potential financial implications
of misinformation in this area for clients, action is needed
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to address this situation. Encouragingly, the findings of this
study have already led to the implementation of some training
initiatives in Victoria, and prompted the development of a
patient brochure in conjunction with the Centre for Genetics
Education.
A major finding of the study is the considerable professional
concern regarding Australian regulation. Very few participants
considered Australian regulations adequate, consistent with the
HGSA’s position statement regarding genetic testing and personal
insurance products (10), which urges the implementation of a
moratorium on the use of genetic test results.
There was no clear consensus among participants regarding
what type of regulation should be implemented, though more
participants agreed with the implementation of legislation than
a moratorium (ban) on the use of genetic test results by insurers.
It is argued elsewhere that a ban should be implemented (with
the exception of mutation-negative results used to counter a
family history of disease), along with longer term regulatory
reform (19).
Regulatory Reform
The model of a self-regulated life insurance industry does
not compel a rigorous standard of evidence regarding which
genetic test results have a sufficient evidence base for use in
underwriting (8). A key recommendation of the Australian
Law Reform Commission’s 2003 inquiry into the protection
of genetic information (20) was the establishment of a body
for this purpose. The Human Genetics Advisory Committee
(HGAC) was established in November 2005 in response to
this recommendation (21). Unfortunately, the HGAC has
since been disbanded (22) and has not been replaced,
meaning this recommendation has not been implemented.
Any longer-term regulatory reform in this area should include
a mechanism for oversight of the level of evidence that
must be satisfied before genetic test results can be used for
underwriting.
Regulatory reform on the use of genetic test results
in life insurance underwriting must be considered by the
Australian government to allow individuals to access genetic
testing without fear of insurance implications. An inquiry
into the life insurance industry has been conducted by the
Joint Parliamentary Committee on Corporations and Financial
Services. The Committee report, tabled in March 2018 (23),
highlights the issues with industry self-regulation and the
need for a moratorium on the use of genetic test results by
insurers. At the time of writing, a moratorium has not been
implemented. Unless the need for regulation is satisfactorily
addressed, the potential for genetic testing to improve health
outcomes for Australians will continue to be limited by insurance
fears.
Our recommendations for addressing the issues identified in
this paper are summarised in Table 2.
Study Limitations
The study has a number of limitations. Its relatively small sample
size of 87 limits its generalisability, providing an indication
of the issues that could be found in the broader professional
workforce with further investigation. Participant demographics
were skewed towards inexperienced professionals, with 59%
having 0–10 years’ experience and senior professionals (>20
years’ experience), constituting only 8% of the sample. It is
difficult to determine whether these percentages accurately
represent the current workforce distribution, given the lack of
publicly available data on this. All participants’ experiences and
attitudes were given equal weight, where participants with many
years of experience and knowledge may have a more informed
view. The survey questions could have better encompassed the
New Zealand regulatory system to allow for more meaningful
comparison.
The findings indicate an emerging clinical issue, highlighted
by a lack of knowledge and/or training by a considerable
proportion of genetics professionals. Individuals and health
service organisations could better address the inconsistency
of training provision and knowledge limitations in this area.
Genetics services are responsible for developing appropriate
policies and ensuring staff are adequately equipped in this
regard. However, collaboration with other genetics services, the
HGSA, and other relevant bodies, such as state governments,
the National Health and Medical Research Council (NHMRC)
and the Centre for Genetics Education (CGE), to develop
a nationally consistent training programme, should be
encouraged.
Research Recommendations
Future research could focus on exploring these issues in a larger
cohort, as well as considering the content of genetic counselling
sessions by direct transcript analysis, further investigation of
the differences between clinical services in various Australasian
locations, and consumer views and experiences regarding genetic
testing and insurance issues.
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